Semaglutide & Your Gallbladder / Kidneys: A Risk Check

When people read the warnings that come with Wegovy, Ozempic, or Rybelsus, two organs tend to raise eyebrows: the gallbladder and the kidneys. The questions are reasonable — does semaglutide cause gallstones? Can it damage my kidneys? The honest answers are more nuanced than the scary version and more cautious than the dismissive one. There is a real, measurable gallbladder signal. The kidney picture is genuinely two-sided: a warning about acute kidney injury associated with volume depletion, alongside proven long-term benefit in a defined diabetic kidney disease population. This guide separates what the FDA label warns about, what the trials show, and what is still being worked out — and it is general education, not medical advice for your situation.

A grounding fact first. Wegovy, Ozempic, and Rybelsus are all semaglutide, a GLP-1 receptor agonist; the injectables and the oral pill share the same molecule (our oral vs injectable semaglutide guide covers the differences in potency and dosing). All three are prescription-only — and the organ cautions below are part of why screening and monitoring happen under a clinician.

The gallbladder: a real, modest signal

This is the clearer of the two stories. Across the GLP-1 drug class, there is a genuine, statistically real increase in gallbladder and biliary problems — gallstones (cholelithiasis), gallbladder inflammation (cholecystitis), and related biliary disease.

The strongest evidence is a 2022 systematic review and meta-analysis in JAMA Internal Medicine that pooled 76 randomized trials covering more than 100,000 patients. It found GLP-1 receptor agonist use was associated with a higher risk of gallbladder or biliary disease overall, and that the risk was greater at higher doses, with longer use, and when the drugs were used for weight loss rather than diabetes¹. That last point matters for Wegovy users specifically, because weight-management dosing sits at the higher end. In absolute terms the increase is modest — most people will never have a gallbladder problem — but it is not nothing, and it is well documented rather than theoretical.

Substantial or rapid weight loss can increase gallstone risk. Weight loss and altered gallbladder motility are possible contributors, but their relative contributions to the observed drug-associated risk are not established¹. The Wegovy label reports more acute gallbladder disease with treatment than placebo even after accounting for the degree of weight loss⁸. That finding does not establish one mechanism for every event.

The practical upshot: be alert for the classic warning signs of a gallbladder attack — pain in the upper-right abdomen (often after fatty meals), pain spreading to the right shoulder or back, fever, or yellowing of the skin or eyes — and treat them as a call-your-clinician situation, not a wait-and-see one. The FDA prescribing information for Wegovy lists acute gallbladder disease among the warnings precisely for this reason⁸. Gallstones also matter because they are a common cause of pancreatitis, which is the other abdominal warning on the label — we break that down in semaglutide and pancreatitis.

The kidneys: a short-term risk and a long-term surprise

The kidney story is where honest framing matters most, because the short-term caution and the long-term evidence point in opposite directions.

The short-term concern: acute kidney injury and fluid loss

The current Wegovy label warns about acute kidney injury due to volume depletion. Postmarketing cases have sometimes required dialysis. Most reported events occurred in people experiencing gastrointestinal reactions such as nausea, vomiting or diarrhea leading to dehydration. The label instructs clinicians to monitor kidney function when reactions could cause volume depletion, particularly during initiation and dose escalation⁸.

That supports early attention to fluid loss; it does not prove that every kidney event has this cause, exclude other forms of injury, or establish how frequently spontaneous reports occur. Staying hydrated does not guarantee prevention. If you cannot keep fluids down, urinate much less or become significantly unwell, seek prompt assessment. Fluid and electrolyte advice must account for kidney disease, heart failure and any prescribed restrictions. Our semaglutide and dehydration guide explains this response. The Wegovy constipation and diarrhea guide covers GI symptoms, while dosing and side effects explains titration.

Kidney stones are a separate question. The Wegovy cardiovascular trial reported urolithiasis in 1.2% with treatment versus 0.8% with placebo; our semaglutide and kidney stones guide explains the population and why urine-chemistry studies do not prove recurrence prevention⁸. For people monitoring urate, semaglutide and gout separates a small observed urate change from evidence about gout attacks or long-term gout treatment.

The long-term surprise: kidney *protection* in diabetic CKD

Here is the part that genuinely flips the script. In people with type 2 diabetes and chronic kidney disease, semaglutide appears to protect the kidneys over the long run.

The landmark evidence is the FLOW trial, published in the New England Journal of Medicine in 2024. In roughly 3,500 adults with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1 mg reduced the risk of major kidney-disease events — a composite including kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes — by 24% versus placebo². The trial was actually stopped early for efficacy. Follow-on analyzes found the cardiovascular and kidney benefits held across the spectrum of CKD severity³, and an earlier mediation analysis had already suggested semaglutide and liraglutide may slow kidney-function decline through effects only partly explained by blood sugar or weight⁴. On the strength of FLOW, the FDA approved Ozempic for this exact population in January 2025 — we walk through the approval in Ozempic for kidney disease: what the FLOW trial showed. (This kidney protection sits alongside a separate, FDA-recognized cardiovascular benefit proven in the SELECT trial — see do Wegovy & Ozempic protect the heart?.)

Two essential caveats keep this honest:

• •FLOW studied people who already had type 2 diabetes and chronic kidney disease. Its results do not automatically mean semaglutide protects the kidneys of a healthy-kidney person taking Wegovy purely for weight loss. The protective finding is specific to a high-risk diabetic-CKD population.
• •Ozempic has a current FDA-approved kidney indication in adults with type 2 diabetes and CKD: reducing sustained eGFR decline, end-stage kidney disease and cardiovascular death. Wegovy does not have that same indication. Product selection and monitoring require a clinician’s assessment⁹.

So the kidney bottom line is layered: a volume-depletion warning requiring individualized care, without a guarantee that hydration prevents every kidney event, sitting alongside strong long-term protective evidence in diabetic kidney disease that does not generalize to everyone.

Who should be extra careful

The cautions above are general, but they sharpen for certain people. Talk to your prescriber before or soon after starting if you have existing kidney disease or reduced kidney function, a history of gallstones or gallbladder disease, or conditions that make dehydration more likely. None of these is an automatic disqualifier — they are reasons to individualize monitoring, which is exactly what the prescribing relationship is for. The trials and label can describe populations; only your clinician can account for you.

A note on compounded and gray-market semaglutide

Everything above is anchored to FDA-approved, standardized semaglutide — Wegovy, Ozempic, Rybelsus — and to randomized trials of that product^1,2,8. Compounded semaglutide from some telehealth and med-spa sources is a different situation: dose accuracy and formulation can vary, titration may be looser, and the clean dose-response relationships behind the gallbladder data — and the careful dehydration monitoring behind the kidney guidance — do not automatically transfer to an unstandardized product. If you are weighing where to get semaglutide, our best semaglutide providers guide compares options on price and oversight, and the pillar Semaglutide: How It Works, Results & Side Effects lays out the full evidence picture.

The honest bottom line

The gallbladder concern is real but modest: GLP-1 drugs measurably raise gallstone and biliary risk, more so at higher weight-loss doses, with weight loss a possible contributor rather than a complete explanation^1,8 — know the warning signs and report them promptly⁸. The kidney concern is two-sided: an acute kidney injury warning associated with volume depletion that calls for prompt assessment of significant fluid loss⁸, set against strong evidence that semaglutide protects the kidneys in people with diabetic kidney disease — a 24% reduction in major kidney events in the FLOW trial² — which does not automatically generalize to healthy-kidney weight-loss users. Ozempic now has a kidney indication for adults with type 2 diabetes and CKD⁹. As always, this is education, not a substitute for the clinician who knows your full medical picture. For more on the early weeks, see when does Wegovy start working?. And for two more organ-specific warnings that sit on the label for very different reasons, see semaglutide and NAION (vision risk), added by regulators in 2025, and the thyroid C-cell tumor boxed warning, which has been there since approval and rests on rodent data rather than human rates. On the other side of the ledger, 2025 also brought a new liver indication — see Wegovy for MASH (fatty liver): the new FDA approval.